네트워크 약리학을 활용한 심상성 건선에 대한 澤瀉의 잠재적 작용 기전 탐색 연구

Abstract

Abstract Objective : This study aimed to elucidate the therapeutic mechanisms of Alismatis Rhizoma in treating psoriasis vulgaris using a network pharmacology approach and to compare them with those of prednisolone and calcipotriol. Methods : Active compounds of Alismatis Rhizoma were screened from the TCMSP database (OB≥30%, DL≥ 0.18). Predict ed target proteins for these compounds were identified using SwissTargetPrediction. Psoriasis-related target genes, as well as those of prednisolone and calcipotriol, were obtained from GeneCards. Common targets were visualized with Venny, and protein–protein interaction (PPI) networks were constructed using STRING and analyzed with Cytoscape. Core genes were identified via topological analysis, and functional enrichment (GO/KEGG) analyses were conducted using ClueGO and Enrichr. Result : Nine active compounds and 302 target proteins of Alismatis Rhizoma were identified. A total of 143 common genes with psoriasis were detected, and 18 core genes—including SRC, AKT1, PIK3CA, TNF, JUN, MAPK1, PIK3CD, and MAPK14—were highlighted. Key pathways identified included the “C-type lectin receptor signaling pathway” and “Lipid and atherosclerosis”, indicating involvement of both immune regulation and lipid metabolism in psoriasis. Unlike prednisolone (primarily targeting anti-inflammatory pathways) and calcipotriol (mainly targeting cell proliferation pathways), Alismatis Rhizoma was predicted to modulate both immune and lipid metabolic processes. Conclusion : Alismatis Rhizoma may offer a multi-target approach to psoriasis vulgaris treatment by regulating both immune responses and lipid metabolism, distinct from conventional treatments. Further in vitro and in vivo studies are needed.